Bio-Techne Corp (TECH)
| Market Cap | 16.40B |
| Revenue (ttm) | 798.97M |
| Net Income (ttm) | 174.95M |
| Shares Out | 38.69M |
| EPS (ttm) | 4.40 |
| PE Ratio | 96.21 |
| Forward PE | 58.82 |
| Dividend | $1.28 |
| Dividend Yield | 0.30% |
| Trading Day | May 7 |
| Last Price | $423.05 |
| Previous Close | $410.98 |
| Change ($) | 12.07 |
| Change (%) | 2.94% |
| Day's Open | 410.75 |
| Day's Range | 408.60 - 429.03 |
| Day's Volume | 216,439 |
| 52-Week Range | 228.24 - 444.83 |
Techne (TECH) delivered earnings and revenue surprises of 19.33% and 7.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MINNEAPOLIS, May 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2021...
MINNEAPOLIS, May 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2021. Third Quarter FY2021 Snapshot Third quarter...
NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its...
BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collaboration to develop an extended workflow solution for protein cha...
MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution fo...
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Techne is in a potential buy area as it gets ready to report earnings on May 6. The stock is about 4% above a 415.09 buy point from a second-stage.
MINNEAPOLIS, April 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope™ technology with relea...
MINNEAPOLIS, April 15, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand, completed an extensive rebranding effort in re...
MINNEAPOLIS, April 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage bioph...
The IBD SmartSelect Composite Rating for Bio-Techne rose from 94 to 96 Wednesday. The post Bio-Techne Gets IBD Stock Rating Upgrade appeared first on Investor's Business Daily.
QGEN vs. TECH: Which Stock Is the Better Value Option?
MINNEAPOLIS, April 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system that a...
MINNEAPOLIS, April 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $21...
MINNEAPOLIS, April 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, May 6, 2021, at 8:00 a.m. CDT to rev...
MINNEAPOLIS, March 29, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extrac...
MINNEAPOLIS, March 26, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its R&D Systems and Novus brands have been named winners of the CiteAb COVID-19 Innovation Award. ...
MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagno...
MINNEAPOLIS, March 15, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnost...
NEW YORK, March 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today it has been named to ...
MINNEAPOLIS, March 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rej...
Bio-Techne Corp (NASDAQ: TECH) has agreed to acquire Asuragen Inc, a provider of genetic carrier screening and oncology testing kits. The deal value includes an initial consideration of $215 million in ...
MINNEAPOLIS and AUSTIN, Texas, March 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and ...
MINNEAPOLIS, March 1, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory, covering...
MINNEAPOLIS, Feb. 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufactur...
MINNEAPOLIS, Feb. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid...
NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Co...
MINNEAPOLIS, Feb. 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 SVB Leerink Global He...
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Cor...
MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge portfolio to ...
Bio-Techne saw its IBD SmartSelect Composite Rating rise to 96 Wednesday, up from 92 the day before. The post Composite Rating For Bio-Techne Jumps To 96 appeared first on Investor's Business Daily.
Bio-Techne Corporation (TECH) CEO Charles Kummeth on Q2 2021 Results - Earnings Call Transcript
Techne (TECH) delivered earnings and revenue surprises of 19.12% and 9.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Bio-Techne (NASDAQ:TECH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 50.00% year over year to $1.62, which beat the estimate of $1...
MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021 Snapshot Second ...
MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, ...
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clini...
MINNEAPOLIS, Nov. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stephens Annual Investment...
Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q1 2021 Results - Earnings Call Transcript
Techne (TECH) delivered earnings and revenue surprises of 25.44% and 9.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MINNEAPOLIS, Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2020. First Quarter FY2021 Snapshot First qu...
MINNEAPOLIS, Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30,...
MINNEAPOLIS, Nov. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthc...
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and partner Bio-Techne Corpor...
MINNEAPOLIS, Oct. 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for Jess an...
MINNEAPOLIS, Oct. 1, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace for approx...
MINNEAPOLIS, Sept. 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing Pract...
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provid... [Read more...]
| Industry Biotechnology | IPO Date Feb 9, 1989 |
| CEO Charles Kummeth | Employees 2,300 |
| Stock Exchange NASDAQ | Ticker Symbol TECH |
Financial Performance
In 2020, Bio-Techne's revenue was $738.69 million, an increase of 3.46% compared to the previous year's $714.01 million. Earnings were $229.30 million, an increase of 138.67%.
Analyst Forecasts
According to 12 analysts, the average rating for Bio-Techne stock is "Buy." The 12-month stock price forecast is 451.11, which is an increase of 6.63% from the latest price.